Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week. [Review]
Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week. [Review]
- 2021
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
Giant cell myocarditis is a rare, often rapidly progressive and potentially fatal, disease due to T-cell lymphocyte-mediated inflammation of the myocardium that typically affects young and middle-aged adults. Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable ventricular arrhythmias, and/or heart block. Diagnosis is often difficult due to its varied clinical presentation and overlap with other cardiovascular conditions. Although cardiac biomarkers and multimodality imaging are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnosis. Combination immunosuppressive therapy, along with guideline-directed medical therapy, has led to a paradigm shift in the management of giant cell myocarditis resulting in an improvement in overall and transplant-free survival. Early diagnosis and prompt management can decrease the risk of transplantation or death, which remain common in patients who present with cardiogenic shock. Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
English
0735-1097
10.1016/j.jacc.2020.11.074 [doi] S0735-1097(20)38134-1 [pii]
*Giant Cells/pa [Pathology]
*Myocarditis/th [Therapy]
Algorithms
Biomarkers/bl [Blood]
Biopsy
Cardiovascular Agents/tu [Therapeutic Use]
Defibrillators, Implantable
Electrocardiography
Endocardium/pa [Pathology]
Heart Transplantation
Heart-Assist Devices
Heart/dg [Diagnostic Imaging]
Humans
Immunosuppressive Agents/tu [Therapeutic Use]
Myocarditis/di [Diagnosis]
Natriuretic Peptide, Brain/bl [Blood]
Troponin I/bl [Blood]
MedStar Heart & Vascular Institute
Journal Article
Review
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
Giant cell myocarditis is a rare, often rapidly progressive and potentially fatal, disease due to T-cell lymphocyte-mediated inflammation of the myocardium that typically affects young and middle-aged adults. Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable ventricular arrhythmias, and/or heart block. Diagnosis is often difficult due to its varied clinical presentation and overlap with other cardiovascular conditions. Although cardiac biomarkers and multimodality imaging are often used as initial diagnostic tests, endomyocardial biopsy is required for definitive diagnosis. Combination immunosuppressive therapy, along with guideline-directed medical therapy, has led to a paradigm shift in the management of giant cell myocarditis resulting in an improvement in overall and transplant-free survival. Early diagnosis and prompt management can decrease the risk of transplantation or death, which remain common in patients who present with cardiogenic shock. Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
English
0735-1097
10.1016/j.jacc.2020.11.074 [doi] S0735-1097(20)38134-1 [pii]
*Giant Cells/pa [Pathology]
*Myocarditis/th [Therapy]
Algorithms
Biomarkers/bl [Blood]
Biopsy
Cardiovascular Agents/tu [Therapeutic Use]
Defibrillators, Implantable
Electrocardiography
Endocardium/pa [Pathology]
Heart Transplantation
Heart-Assist Devices
Heart/dg [Diagnostic Imaging]
Humans
Immunosuppressive Agents/tu [Therapeutic Use]
Myocarditis/di [Diagnosis]
Natriuretic Peptide, Brain/bl [Blood]
Troponin I/bl [Blood]
MedStar Heart & Vascular Institute
Journal Article
Review